Perthera

Mclean, United States Founded: 2012 • Age: 14 yrs
Molecular cancer profiling is conducted via genomics and proteomics.

About Perthera

Perthera is a Healthcare company based in Mclean (United States) founded in 2012. Molecular cancer profiling is conducted via genomics and proteomics. Perthera has raised $17.02 million across 5 funding rounds from investors including Pilot Growth Equity Partners. The company has 13 employees. Perthera offers products and services including Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its legal entity is PERTHERA INC. Its competitors include Denali Therapeutics, MiRagen and Tempus; 3 of its 3 listed competitors have raised funding.

Company details

Perthera was founded in 2012 and is based in McLean, United States, operating in the biotechnology sector focused on oncology. Personalized molecular profiling of tumors is facilitated through genomics and proteomics analyses. The PrecisOn process is employed to integrate these analyses with patient medical history in the Expert Oncologist system (ExpO), a database that incorporates current clinical research and drug information for oncologist guidance.

Key Metrics

Products & Services of Perthera

Perthera offers a comprehensive portfolio of products and services, including Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline.

Perthera Report
Decision Support Tool

Ranks therapy options for cancer patients using AI analysis.

Virtual Molecular Tumor Board
Collaboration Platform

Facilitates physician collaboration for oncology expertise.

RWE Data Pipeline
Data Analysis Service

Processes real-world evidence for clinical trial matching.

Funding Insights of Perthera

Perthera has successfully raised a total of $17.02M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.47 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $17.02M
  • Total Rounds 5
  • Last Round Series A β€” $4.47M
  • First Round $1.27M

    (Aug 2015)

  • Investors Count 1

All 5 funding rounds of Perthera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2022$4.47MSeries A––
–
Jan 2019$2.1MSeries A––
–
Jun 2016$9.17MSeries A–Pilot Growth Equity
–
Dec 2015$100,000Debt – Conventional––
–
Aug 2015$1.27MSeed––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Perthera

Perthera has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Pilot Growth Equity Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Growth equity investments are provided to technology entrepreneurs.
pilotgrowth.comSan Francisco, USA
Premium access

Investor details for Perthera

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Perthera

20 people are tracked at Perthera (10 in leadership, 8 in board & advisors, 2 in team); the tracked headcount is 13.

NameRoleGroup
Senait Fesseha
VP, FinanceLeadership
Alex Stanwick
Director Healthcare Alliances/Oncology SalesLeadership
Aurelija Urbonaviciute
Director, Software EngineeringLeadership
Nancy Tinnel Emrick
Vice President OperationsLeadership
Michael Pishvaian
Chief Medical OfficerLeadership
Edik Blais
Vice President ResearchLeadership
Patricia De Arbeloa
Medical DirectorLeadership
Aurelija Striuze
Director, European operationsLeadership
Emanuel Petricoin
Chief Scientific OfficerLeadership
Jeanne Cummins
Chief Marketing Officer (cmo)Leadership
Andrew Black
Board MemberBoard & advisors
John L. Marshall
Scientific AdvisorBoard & advisors
Jonathan Brody
Scientific AdvisorBoard & advisors
James Winnefeld Jr.
Senior AdvisorBoard & advisors
Yehuda Neuberger
Board MemberBoard & advisors
Einaras Von Gravrock
Board MemberBoard & advisors
Margot P. Schoenborn
Board ObserverBoard & advisors
Nan Hayworth
Board MemberBoard & advisors
Saulius Žemaitaitis
Software EngineerTeam
Dzung Thach
Computational BiologistTeam
Premium access

Complete people profiles for Perthera

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Perthera

3 dated milestones of Perthera across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Perthera is founded.
  2. Funding First funding round of $1.3M.
  3. Funding Latest funding round, Series A, of $4.5M.

Competitors of Perthera

Perthera has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Tempus.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
denalitherapeutics.com2015San Francisco, United States$347M377
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
miragen.com2007Boulder, United States$111.29M92
MicroRNA-based therapeutics are developed for treating multiple diseases.
tempus.com2015Chicago, United States$1.05B772
AI-based precision medicine solutions for oncology are provided.
Premium access

Detailed competitors of Perthera

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Clinical IT & Data Platforms

3 companies that operate in the same segment as Perthera (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Employee health benefits are facilitated via a cloud-based platform.
2007Plymouth Meeting, Pennsylvania, United StatesUSD 228.3 M
Healthcare appointments are booked online via Zocdoc's platform.
2007New York, New York, United StatesUSD 425.97 MUSD 4.66 M1,365
Virtual physical therapy and digital pain care solutions are provided.
2015San Francisco, California, United StatesUSD 854.44 M1,746
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Perthera

Premium access

Complete news archive for Perthera

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Perthera

Perthera was founded in 2012 and raised its 1st funding round 3 years after it was founded.

Perthera is headquartered in Mclean, United States. It is registered at Mclean, Virginia, United States.

Perthera is a funded company, having raised a total of $17.02M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.27M, raised on Aug 2015.

Perthera has 13 employees.

Perthera was founded in 2012 and is based in McLean, United States, operating in the biotechnology sector focused on oncology. Personalized molecular profiling of tumors is facilitated through genomics and proteomics analyses. The PrecisOn process is employed to integrate these analyses with patient medical history in the Expert Oncologist system (ExpO), a database that incorporates current clinical research and drug information for oncologist guidance.

Perthera's top competitors include Tempus, Denali Therapeutics and MiRagen.

Perthera offers Perthera Report, Virtual Molecular Tumor Board, and RWE Data Pipeline.

Perthera has 1 investor. Key investors include Pilot Growth Equity Partners.

Perthera operates through Perthera Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available